clinical trial · NCT03971253
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Rheumatoid Arthritis (RA)Peficitinib
brief summary
The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.
started
Sep 2, 2019
primary completion
May 31, 2026
completion
May 31, 2026
last updated
Apr 6, 2026
detailed description
This is a mandatory Post-Marketing Surveillance (PMS) requested by Pharmaceuticals and Medical Devices Agency (PMDA) as a part of the Japan-Risk Management Plan (J-RMP).
official title
Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol